1,167 reports of this reaction
2.0% of all PROPOFOL reports
#8 most reported adverse reaction
BRADYCARDIA is the #8 most commonly reported adverse reaction for PROPOFOL, manufactured by Fresenius Kabi USA, LLC. There are 1,167 FDA adverse event reports linking PROPOFOL to BRADYCARDIA. This represents approximately 2.0% of all 57,130 adverse event reports for this drug.
PROPOFOL has an overall safety score of 95 out of 100. Patients taking PROPOFOL who experience bradycardia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BRADYCARDIA is a less commonly reported adverse event for PROPOFOL, but still significant enough to appear in the safety profile.
In addition to bradycardia, the following adverse reactions have been reported for PROPOFOL:
The following drugs have also been linked to bradycardia in FDA adverse event reports:
BRADYCARDIA has been reported as an adverse event in 1,167 FDA reports for PROPOFOL. This does not prove causation, but indicates an association observed in post-market surveillance data.
BRADYCARDIA accounts for approximately 2.0% of all adverse event reports for PROPOFOL, making it a notable side effect.
If you experience bradycardia while taking PROPOFOL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.